GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

A recent report raised concerns that it contains high levels of the heavy metal. Here’s what that may mean for your health.

Pride Month may be over, but a focus on addressing health disparities for the LGBTQ+ community in Olmsted County isn’t ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic ...